Role of NRF2 in lung cancer
M Sánchez-Ortega, AC Carrera, A Garrido - Cells, 2021 - mdpi.com
The gene expression program induced by NRF2 transcription factor plays a critical role in
cell defense responses against a broad variety of cellular stresses, most importantly …
cell defense responses against a broad variety of cellular stresses, most importantly …
[HTML][HTML] Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer
X Liu, P Wang, C Zhang, Z Ma - Oncotarget, 2017 - ncbi.nlm.nih.gov
Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role
of noncoding RNA regulatory networks has been more and more reveal. EGFR has been …
of noncoding RNA regulatory networks has been more and more reveal. EGFR has been …
[HTML][HTML] KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Lung squamous cell carcinoma (LUSC) represents a major subtype of lung cancer with
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung …
N Thatcher, FR Hirsch, AV Luft, A Szczesna… - The lancet …, 2015 - thelancet.com
Background Necitumumab is a second-generation, recombinant, human immunoglobulin
G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus …
G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus …
Small cell lung cancer: will recent progress lead to improved outcomes?
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique
natural history characterized by a short doubling time, high growth fraction, and early …
natural history characterized by a short doubling time, high growth fraction, and early …
Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy
L Boyero, A Sánchez-Gastaldo, M Alonso… - Cancers, 2020 - mdpi.com
Simple Summary Immuno-oncology has redefined the treatment of lung cancer, with the
ultimate goal being the reactivation of the anti-tumor immune response. This has led to the …
ultimate goal being the reactivation of the anti-tumor immune response. This has led to the …
Lung cancer in the era of precision medicine
K Politi, RS Herbst - Clinical cancer research, 2015 - AACR
The past decade has been transformative for lung cancer patients, physicians, and
scientists. The discovery of EGFR mutations that confer sensitivity to tyrosine kinase …
scientists. The discovery of EGFR mutations that confer sensitivity to tyrosine kinase …
DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors
PH Hoang, MT Landi - Cancers, 2022 - mdpi.com
Simple Summary Aberrant DNA methylation is associated with multiple malignancies,
including lung cancer. Differences in methylation patterns have been observed across lung …
including lung cancer. Differences in methylation patterns have been observed across lung …
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
T Jiang, J Shi, Z Dong, L Hou, C Zhao, X Li… - Journal of hematology & …, 2019 - Springer
Introduction To depict the genomic landscape of Chinese early-stage lung squamous cell
carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 …
carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 …
Targeting the complement pathway as a therapeutic strategy in lung cancer
EK Kleczko, JW Kwak, EL Schenk… - Frontiers in …, 2019 - frontiersin.org
Lung cancer is the leading cause of cancer death in men and women. Lung
adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances …
adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances …